

OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-16 22:31:15

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Contagious equine metritis
Address of laboratory:	USDA, APHIS, Veterinary Services P.O. Box 844 Ames, Iowa 50010 UNITED STATES OF AMERICA
Tel.:	+1.515 337.75.65
Fax:	+1.515 337.75.69
E-mail address:	Suelee.Robbe-Austerman@usda.gov
Website:	www.aphis.usda.gov/nvsl
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Karl J. Hochstein, Acting Director, National Veterinary Services Laboratories, DB, VS, APHIS, USDA
Name (including Title and Position) of OIE Reference Expert:	Matthew M. Erdman, Senior Staff Veterinarian, Center for Veterinary Biologics, STASDB, VS, APHIS, USDA
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
Compliment Fixation	Yes	1104	193
Direct diagnostic tests			
Identification of the Agent	Yes	871	205
Real-Time PCR	Yes	2	1

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Culture control isolates	Identification of the Agent	Produced	16 ml	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Modified Timoney-Shin Agar	Identification of the Agent	Produced	670 ea	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Eugon agar with 10% chocolated horse blood	Identification of the Agent	Produced	720 ea	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
CEM High Positive control sera	Complement Fixation	Produced	15 ml	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new

procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
BELGIUM	Feb, Mar, May, Jun, Jul, Aug, Sep, Oct, Dec	197	0
GERMANY	Feb, Mar, Apr, May, Jun, Oct, Nov	11	0
DOMINICAN (REP.)	Jan, Sep, Nov	16	0
FRANCE	Jan	1	0
UNITED KINGDOM	Mar, May, Jun, Jul, Nov, Dec	9	0
IRELAND	Jan, May	5	0
THE NETHERLANDS	Jan, Apr, May, Jun, Jul, Aug, Sep, Oct, Nov, Dec	65	1

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
KOREA (REP. OF)	Provide sequencing and analysis of isolates from South Korea.	E-mail
SOUTH AFRICA	Continued communication on analysis of sequenced isolates	E-mail

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Evaluation of PCR reproducibility	18 months, ongoing	Provide additional reproducibility data for PCR assays to support validation data.	11 total laboratories including Animal and Plant Health Agency Bury St Edmunds Rougham Hill ; Wageningen Bioveterinary Research Department of Bacteriology & Epidemiology	THE NETHERLANDS UNITED KINGDOM

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Number of horses and samples tested for import purposes. Number of positive identifications within the country

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

Import horse and sample test numbers.

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 1

Workshop of EU-RL for equine diseases, October 3, Paris France: Presentation titled: Advancing Molecular Typing Tools for *T. equigenitalis* to Support Epidemiological Tracing

c) National conferences: 0

United States Animal Health Association annual meeting: as needed, no presentation in 2019 due to absence of disease activity.

d) Other:

(Provide website address or link to appropriate information) 1

<https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/animal-disease-information/horse-disease-information/cem/contagious-equine-metritis>

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17043 Proficiency Testing Provider	A2LA Scope 17043 2526-06.pdf
ISO 17025 Biological Testing	A2LA Scope 17025 2526-01.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Taylorella species isolation and identification	A2LA
Contagious Equine Metritis Compliment Fixation Test	A2LA
Taylorella species real-time PCR - identification of the agent	A2LA
Proficiency Panel Contagious Equine Metritis Isolation from Culture	A2LA

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Workshop of EU-RL for equine diseases	October 2019	Paris, France	Speaker	Advancing Molecular Typing Tools for <i>T. equigenitalis</i> to Support Epidemiological Tracing

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Collaborative Project to Evaluate PCR	Currently it is difficult for any one country or laboratory to evaluate direct PCR for this disease due to the small number of positive samples and lack of diversity of isolates when positive samples are available. By validating assays as a collaborative effort, the diversity and number of positive swabs can be expanded.	National Veterinary Services Laboratories; Animal and Plant Health Agency Bury St Edmunds Rougham Hill ; Wageningen Bioveterinary Research Department of Bacteriology & Epidemiology

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Organized culture-based proficiency testing for continued approval of testing personnel within the United States.	13	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

For ToR 4, Diagnostic testing - we also provided testing for the European Union (export and semen export) 89 samples for provision of diagnostic support in the months of Jan, Feb, Apr, May, Jun, Jul, Aug, Sep, Oct, Nov, Dec

For ToR 4, Diagnostic testing - Our laboratory oversees a network of 13 laboratories in the United States authorized to perform CEM culture testing. During fiscal year 2019, these laboratories performed testing of a total of 1410 horses (greater than 12,000 samples) from CEM affected countries imported into the United States for permanent entry.

For ToR 7, # 14: Our laboratory provides an annual training course for laboratory personnel in the United States. All personnel at laboratories in the US that perform CEM culture must attend this training. Training is available for international participants on a by request basis. No international requests were received in 2019

For ToR5, #10: Eleven laboratories participated. The exact participants are kept confidential, I listed the three labs and countries heading the study.